Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for early postoperative mood after laparoscopic total hysterectomy
ChiCTR2100050008Phase 4Not yet recruiting
- Sponsor
- Hefei Second People's Hospital
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in anxiety disorder, major depressive disorder (MDD) and postoperative pain (2 arms), sponsored by Hefei Second People's Hospital. Primary endpoints: Duration of anesthesia, surgery and orientation recovery time, Visual Analogue Score (VAS) and 5 more. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
anxiety disordermajor depressive disorder (MDD)postoperative pain
Beyond the preview
Go deeper on ChiCTR2100050008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050008.